Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes with Trisomy 8 and/or Monosomy 7

MV Latypova, NN Mamaev, TL Gindina, AI Shakirova, OV Paina, AA Osipova, TV Rudakova, EV Morozova, SN Bondarenko, LS Zubarovskaya

RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022

For correspondence: Prof. Nikolai Nikolaevich Mamaev, MD, PhD, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022; e-mail: nikmamaev524@gmail.com

For citation: Latypova MV, Mamaev NN, Gindina TL, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes with Trisomy 8 and/or Monosomy 7. Clinical oncohematology. 2022;15(2):198–204. (In Russ).

DOI: 10.21320/2500-2139-2022-15-2-198-204


ABSTRACT

The study assessed the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 34 patients with cytogenetically verified variants of myelodysplastic syndrome (MDS) with trisomy 8 and/or monosomy 7, who were treated at the RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation from 2013 to 2020. Both adult and pediatric MDS were analyzed without excluding the variants with two additional chromosomal abnormalities or complex karyotype. The study revealed that а) allo-HSCT should be performed in the treatment of both MDS variants; b) the outcomes of trisomy 8 treatment appeared to be better; c) children with monosomy 7 showed a higher rate of toxic complications in allo-HSCT.

Keywords: myelodysplastic syndromes, cytogenetic variants, trisomy 8, monosomy 7, allo-HSCT.

Received: October 2, 2021

Accepted: March 6, 2022

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9939):2239–52. doi: 10.1016/S0140-6736(13)61901-7.
  2. Robin M, Porcher R, Zinke-Cerwenka W, et al. Allogeneic hematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017;52(2):209–15. doi: 10.1038/bmt.2016.266.
  3. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120(7):1395–409. doi: 10.1182/blood-2012-04-423046.
  4. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):1943–64. doi: 1182/blood-2013-03-492884.
  5. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from international database merge. J Clin Oncol. 2012;50(8):820–9. doi: 10.1200/JCO.2011.35.6394.
  6. Nevill TJ, Shepherd JD, Sutherland HJ, et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):205–13. doi: 10.1016/j.bbmt.2008.11.015.
  7. Koenecke C, Gohring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica. 2015;100(3):400–8. doi: 10.3324/haematol.2014.116715.
  8. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy- related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13(6):655–64. doi: 10.1016/j.bbmt.2007.01.079
  9. Konuma T, Miyazaki Y, Ohashi K, et al. Outcomes of allogeneic hematopoietic stem cell transplantation in adults patients with myelodysplastic syndrome harboring trisomy 8. Biol Blood Marrow Transplant. 2017;23(1):75–80. doi: 10.1016/j.bbmt.2016.10.015.
  10. Trobaugh-Lotrario AD, Kletzel M, Quinones RR, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant. 2005;25(2):143–9. doi: 10.1038/sj.bmt.1704753.
  11. Al-Anazi KA. Myelodysplastic disorders, monosomy 7. In: Fuchs O, ed. Myelodysplastic syndromes. IntechOpen; 2016. рр. 131–61. doi: 10.5772/64549.
  12. Itonaga Y, Ishiyama K, Aoki K, et al. Clinical Impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(9):1471–81. doi: 10.1038/s41409-019-0469-5.
  13. Komrokji RS, Padron E, Ebert BL, et al. Deletion 5q MDS: Molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013;26(4):365–75. doi: 1016/j.beha.2013.10.013.
  14. Gindina TL, Mamaev NN, Afanasyev BV. Chromosome Abnormalities and Hematopoietic Stem Cell Transplantation in Acute Leukemias. In: Larramendy ML, Soloneski S, eds. Chromosomal Abnormalities – A hallmark manifestation of genomic instability. IntechOpen; 2017. рр. 71–86. doi: 10.5772/67802.
  15. Schaffer L, McGovan-Jordan L, Schmid M. An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2013. 140 p.
  16. Гиндина Т.Л. Характеристика основных цитогенетических изменений у больных острыми лейкозами и их связь с результатами аллогенной трансплантации стволовых клеток: Дис.… д-ра мед. наук. СПб., 2019. 373 с.
    [Gindina TL. Kharakteristika osnovnykh tsitogeneticheskikh izmenenii u bol’nykh ostrymi leikozami i ikh svyaz’ s rezul’tatami allogennoi transplantatsii stvolovykh kletok. (The characteristics of major cytogenetic changes in acute leukemia patients and their association with the outcomes of allogeneic stem cell transplantation.) [dissertation] Saint Petersburg; 2019. 373 p. (In Russ)]
  17. Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021;39(11):1223–33. doi: 10.1200/JCO.20.01659.
  18. Мамаев Н.Н., Латыпова М.В., Шакирова А.И. и др. Роль BAALC-экспрессирующих лейкозных клеток-предшественниц в патогенезе миелодиспластических синдромов. Клиническая онкогематология. 2022;15(1):62–8. doi: 10.21320/2500-2139-2022-15-1-62-68.
    [Mamaev NN, Latypova MV, Shakirova AI, et al. The Role of BAALC-Expressing Leukemia Precursor Cells in the Pathogenesis of Myelodysplastic Syndromes. Clinical oncohematology. 2022;15(1):62–8. doi: 10.21320/2500-2139-2022-15-1-62-68. (In Russ)]